I et 3- måneders studie med 302 patienter med let stabilt hjertesvigt, som alle var i standardbehandling for stabilt hjertesvigt blev tillæg af Sprimeo 150 mg godt tolereret.
In a 3-month study of 302 patients with mild stable heart failure, all of whom were receiving standard therapy for stable heart failure, addition of Sprimeo 150 mg was well tolerated.